Beactica to present LSD1 programme at the AACR Annual Meeting 2019
Uppsala, Sweden – 29 January 2019
Beactica AB, the Swedish drug discovery company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research’s Annual Meeting 2019. The conference will take place on 29 March – 3 April, 2019 at Georgia World Congress Center in Atlanta, USA.
Dr Ulf Bremberg, Chief Scientific Officer, to present poster entitled LSD1 Modulation By Allosteric Ligands on Tuesday 2 Apr 2019 at 1:00 PM – 5:00 PM. The location is the Georgia World Congress Center, Exhibit Hall B. The session category is Experimental and Molecular Therapeutics and the session title is Epigenetic Targets.
Beactica’s poster presentation will include new positive results from in vivo efficacy studies using unique models based on patient-derived glioblastoma stem cells. Results from further in vivo efficacy studies in models based on cell lines of prostate cancer, malignant melanoma and Ewing’s sarcoma will also be presented.
Organised by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world. It has an anticipated attendance of more than 20 000 scientists, clinicians, advocates, and other attendees. The event spans integrative cancer science, global impact, individualised patient care and showcases the best and most up-to-date cancer science available.
About Beactica's LSD1 programme
Beactica’s LSD1 programme is focused on the development of first-in-class small molecule allosteric modulators of LSD1 that have a mechanism of action that is fundamentally different from the catalytic LSD1 inhibitors currently in clinical development. Non-toxic doses of Beactica’s compounds induce significant reduction of LSD1 protein in treated cells, indicating potential for a broad oncology scope. The programme has received funding from the Swedish Governmental Agency for Innovation Systems (VINNOVA) as well as the European innovation fund, Horizon 2020.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes in areas of unmet medical need, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform. Founded in 2006 based on research carried out at Uppsala University, Beactica has established a reputation as a world-leader in fragment-based drug discovery using SPR biosensor technology. For more information on Beactica, please visit www.beactica.com.